Effects of the combined treatment of naloxone and indomethacin on catecholamines and behavior after intranigral lipopolysaccharide injection.
The present study examined effects of the combined administration of naloxone (NX) and indomethacin (IM) on nigrostriatal catecholamines and locomotor activity after intranigral lipopolysaccharide (LPS) injection in Sprague-Dawley rats. NX plus IM was given 3 days after LPS injection; it significantly (P < .05) reversed LPS inflammation on nigrostriatal dopamine (DA) and nigral serotonin (5-HT) and nigral homovanillic acid (HVA)/DA ratio and nigrostriatal 5-hydroxyindoleacetic acid (5-HIAA)/5-HT ratio. It also tended to ameliorate the locomotor hyperactivity. However, NX plus IM given 30 min before LPS could not satisfactorily protect against LPS's damage both biochemically and behaviorally. These results reveal that NX plus IM may protect against LPS on DA, 5-HT, and motor function after LPS injection but not before. Thus it suggests that the combined treatment of NX and IM gives a potent therapy, but not prevention, of LPS-induced inflammation and also protect nigrostriatal dopaminergic and serotoninergic systems against LPS in rats.
Wang
Vinchi
V
Section of Neurology, Cardinal Tien Hospital, Taipei, Taiwan, Republic of China.
Chia
Lie-Gan
LG
Ni
Dah-Ren
DR
Cheng
Lee-Ju
LJ
Ho
Yuh-Pin
YP
Cheng
Fu-Chou
FC
Hong
Jau-Shyong
JS
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D002395:Catecholamines / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004334:Drug Administration Schedule; D004357:Drug Synergism; D007213:Indomethacin / Q000008:administration & dosage*; D007267:Injections; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009270:Naloxone / Q000008:administration & dosage*; D009292:Narcotic Antagonists / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002395:Catecholamines; D008070:Lipopolysaccharides; D009292:Narcotic Antagonists; D012701:Serotonin; D009270:Naloxone; D004298:Dopamine; D007213:Indomethacin